Capital One initiated coverage of ANI Pharmaceuticals with an Overweight rating and $80 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANIP:
- ANI Pharmaceuticals: Current Performance Insights Revealed
- ANI Pharmaceuticals price target raised to $77 from $70 at Guggenheim
- ANI Pharmaceuticals price target raised to $83 from $73 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $80 from $72 at Truist
- ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
